Analyst Price Targets — KRYS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 12:56 pm | Geulah Livshits | Chardan Capital | $323.00 | $282.65 | TheFly | Krystal Biotech price target raised to $323 from $220 at Chardan |
| February 17, 2026 6:26 pm | Roger Song | Jefferies | $371.00 | $291.10 | TheFly | Krystal Biotech price target raised to $371 from $310 at Jefferies |
| January 30, 2026 12:31 pm | — | Goldman Sachs | $327.00 | $279.34 | TheFly | Krystal Biotech price target raised to $327 from $206 at Goldman Sachs |
| January 9, 2026 11:08 am | — | H.C. Wainwright | $310.00 | $248.91 | TheFly | Krystal Biotech price target raised to $310 from $240 at H.C. Wainwright |
| October 17, 2025 10:44 am | Debjit Chattopadhyay | Guggenheim | $224.00 | $188.33 | TheFly | Krystal Biotech price target raised to $224 from $189 at Guggenheim |
| August 22, 2025 12:03 pm | — | Chardan Capital | $216.00 | $150.49 | TheFly | Krystal Biotech price target lowered to $216 from $219 at Chardan |
| September 11, 2024 6:53 am | Dae Gon Ha | Stifel Nicolaus | $220.00 | $185.00 | TheFly | Krystal Biotech price target raised to $220 from $204 at Stifel |
| September 2, 2024 7:20 am | Alec Stranahan | Bank of America Securities | $205.00 | $195.12 | TheFly | Krystal Biotech price target raised to $205 from $195 at BofA |
| August 12, 2024 8:23 am | Gavin Clark-Gartner | Evercore ISI | $206.00 | $182.17 | TheFly | Krystal Biotech price target raised to $206 from $201 at Evercore ISI |
| April 15, 2024 4:25 pm | Dae Gon Ha | Stifel Nicolaus | $204.00 | $169.75 | StreetInsider | Krystal Biotech (KRYS) PT Raised to $204 at Stifel |
Latest News for KRYS
Redmile Group bought 16,317 shares of Krystal Biotech; the estimated trade size was $3.43 million based on average closing prices in the fourth quarter. The quarter-end value of the Krystal Biotech position increased by $50.33 million, reflecting both trading and price movement effects.
KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.
Krystal Biotech, Inc. (NASDAQ: KRYS - Get Free Report) shares gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $276.45, but opened at $289.00. Krystal Biotech shares last traded at $285.45, with a volume of 212,409 shares. The company reported $1.70 earnings per
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Krystal Biotech remains a "Buy" as VYJUVEK's strong launch powers profitability, and pipeline catalysts offer further upside. Krystal Biotech's valuation is underpinned by VYJUVEK's blockbuster trajectory, high gross margins (94%), and disciplined R&D and SG&A spending. Phase 1 KB407 data in cystic fibrosis confirms molecular proof-of-concept, with a $2B+ opportunity targeting modulator-ineligible and suboptimal…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KRYS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.